Daptomycin 6mg/kg/day
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasciitis, Necrotizing
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Trial Timeline
Jun 1, 2005 → May 1, 2008
NCT ID
NCT00261807About Daptomycin 6mg/kg/day
Daptomycin 6mg/kg/day is a pre-clinical stage product being developed by Merck for Fasciitis, Necrotizing. The current trial status is completed. This product is registered under clinical trial identifier NCT00261807. Target conditions include Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00261807 | Pre-clinical | Completed |
Competing Products
3 competing products in Fasciitis, Necrotizing
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Botulinum toxin type A + Placebo | Ipsen | Phase 2/3 | 62 |
| Saline Injection | MiMedx Group | Phase 2/3 | 60 |
| Saline Injection | MiMedx Group | Phase 3 | 72 |